未登录

A

Amy L. Olson

boehringer ingelheim pharmaceuticals, inc

H指数:32

被引数:6,163

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Workplace Productivity Loss in Patients with Progressive Pulmonary Fibrosis: Data from the ILD-PRO Registry

进展性肺纤维化患者的工作场所生产效率损失：ILD-PRO登记研究数据

IF3.9

2026-05-270

PREAI

Real-world clinical and economic outcomes associated with supplemental oxygen therapy use among patients with fibrosing interstitial lung disease in the United States

美国纤维化间质性肺疾病患者补充氧疗使用相关的真实世界临床和经济结局

BMC Pulmonary Medicine

IF2.8

2025-11-180

OAAI

Real-world care patterns and specialist encounters of patients with systemic autoimmune rheumatic disease-related interstitial lung disease in the United States: a retrospective administrative claims database analysis

美国系统性自身免疫性风湿病相关间质性肺病患者真实世界的护理模式及专科就诊情况：一项回顾性行政索赔数据库分析

IF4.4

2025-04-230

PRE

Early nintedanib deployment in COVID-19 interstitial lung disease (ENDCOV-I): study protocol of a randomised, double-blind, placebo-controlled trial

BMJ OPEN RESPIRATORY RESEARCH

IF3.4

2025-04-100

OAAI

Predictors of Long-Term Survival in Patients with Idiopathic Pulmonary Fibrosis: Data from the IPF-PRO Registry

特发性肺纤维化患者长期生存的预测因素：IPF-PRO注册研究的数据

IF3.9

2025-03-090

OA

Supplemental oxygen therapy use among patients with fibrosing interstitial lung disease in the United States

在美国，纤维化间质性肺疾病患者中补充性氧疗的使用情况

RESPIRATORY RESEARCH

IF5

2025-02-280

OA

Proportion and predictors of FVC decline in patients with interstitial lung disease

间质性肺疾病患者FVC下降的比例和预测因素

RESPIRATORY MEDICINE

IF3.1

2024-06-010

OAAI

Trajectories of health-related quality of life (HRQL) in patients with idiopathic pulmonary fibrosis (IPF)

EUROPEAN RESPIRATORY JOURNAL

IF21

2023-10-270

PRE

Characteristics of patients with progressive fibrosing ILDs in the ILD-PRO Registry

EUROPEAN RESPIRATORY JOURNAL

IF21

2023-10-271

PRE

Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline

成人特发性肺纤维化 (更新) 和进行性肺纤维化官方ATS/ERS/JRS/ALAT临床实践指南

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

IF19.4

2022-05-011.1K

OAAI

Raghu, Ganesh; Remy-Jardin, Martine; Richeldi, Luca; Thomson, Carey C.; Inoue, Yoshikazu; Johkoh, Takeshi; Kreuter, Michael; Lynch, David A.; Maher, Toby M.; Martinez, Fernando J.; Molina-Molina, Maria; Myers, Jeffrey L.; Nicholson, Andrew G.; Ryerson, Christopher J.; Strek, Mary E.; Troy, Lauren K.; Wijsenbeek, Marlies; Mammen, Manoj J.; Hossain, Tanzib; Bissell, Brittany D.; Herman, Derrick D.; Hon, Stephanie M.; Kheir, Fayez; Khor, Yet H.; Macrea, Madalina; Antoniou, Katerina M.; Bouros, Demosthenes; Buendia-Roldan, Ivette; Caro, Fabian; Crestani, Bruno; Ho, Lawrence; Morisset, Julie; Olson, Amy L.; Podolanczuk, Anna; Poletti, Venerino; Selman, Moises; Ewing, Thomas; Jones, Stephen; Knight, Shandra L.; Ghazipura, Marya; Wilson, Kevin C.

Healthcare Resource Utilization and Related Costs in Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype: A US Claims Database Analysis

具有进行性表型的慢性纤维化间质性肺疾病的医疗资源利用和相关成本: 美国索赔数据库分析

ADVANCES IN THERAPY

IF4

2022-02-235

OAAI

Prevalence and Incidence of Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype in the United States Estimated in a Large Claims Database Analysis

在大型索赔数据库分析中估计的美国具有进行性表型的慢性纤维化间质性肺病的患病率和发病率

ADVANCES IN THERAPY

IF4

2021-06-1727

OAAI

Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey

进行性纤维化间质性肺疾病患病率的估计: 系统文献综述和医师调查数据

ADVANCES IN THERAPY

IF4

2020-12-1461

OAAI

Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA

基于美国保险索赔的非IPF进行性纤维化间质性肺疾病患者的医疗资源利用和成本

ADVANCES IN THERAPY

IF4

2020-05-2121

OAAI

Trends in Idiopathic Pulmonary Fibrosis-related Mortality in the United States: 2000-2017

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

IF19.4

2019-10-0139

PREAI

The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype

EUROPEAN RESPIRATORY REVIEW

IF10.4

2018-12-21143

OAAI

Prevalence of progressive fibrosing interstitial lung disease

EUROPEAN RESPIRATORY JOURNAL

IF21

2018-11-197

PRE

Health care resources utilisation and costs in patients with non-IPF progressive fibrosing interstitial lung disease

EUROPEAN RESPIRATORY JOURNAL

IF21

2018-11-191

PRE

Rheumatoid Arthritis-Interstitial Lung Disease in the United States: Prevalence, Incidence, and Healthcare Costs and Mortality

JOURNAL OF RHEUMATOLOGY

IF3.4

2018-11-15151

OAAI

The impact of carrying supplemental oxygen on exercise capacity and dyspnea in patients with interstitial lung disease

RESPIRATORY MEDICINE

IF3.1

2018-05-0120

OAAI